PRAMEF5
PRAME family member 5
Also known as: PRAM5_HUMAN, PRAMEF23, PRAMEF5L
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5TYX0
- Gene
- PRAMEF5
- Ensembl
- ENSG00000270601
- Chromosome
- 1
- Canonical length
- 476 aa
- Protein class
- Predicted intracellular proteins
OverviewNCBI Gene
Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul2-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
476 residues, UniProt reviewed canonical sequence.
>Q5TYX0|PRAMEF5
1 MSIRTPPRLL ELAGRSLLRD QALAMSTLEE LPTELFPPLF MEAFSRRRCE ALKLMVQAWP
61 FRRLPLRPLI KMPCLEAFQA VLDGLDALLT QGVHPRRWKL QVLDLQDVCE NFWMVWSEAM
121 AHGCFLNAKR NKKPVQDCPR MRGQQPLTVF VELWLKNRTL DEYLTCLLLW VKQRKDLLHL
181 CCKKLKILGM PFRNIRSILK MVNLDCIQEV EVNCKWVLPI LTQFTPYLGH MRNLQKLVLS
241 HMDVSRYVSP EQKKEIVTQF TTQFLKLCCL QKLSMNSVSF LEGHLDQLLS CLKTSLKVLT
301 ITNCVLLESD LKHLSQCPSI SQLKTLDLSG IRLTNYSLVP LQILLEKVAA TLEYLDLDDC
361 GIIDSQVNAI LPALSRCFEL NTFSFCGNPI SMATLENLLS HTIILKNLCV ELYPAPRESY
421 DADGTLCWSR FPQIRAELMK RVRDLRHPKR ILFCTDCCPD CGNRSFYDLE ADQCCCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PRAMEF5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 0 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
- blood vessel: 0 nTPM
Single-cell type
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
- alveolar cells type 1: 0 nCPM
- alveolar cells type 2: 0 nCPM
- b-cells: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of apoptotic process
- negative regulation of cell differentiation
- negative regulation of DNA-templated transcription
- positive regulation of cell population proliferation
- proteasome-mediated ubiquitin-dependent protein catabolic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PRAMEF5 as an antibody target. Whether an autoantibody or antibody against PRAMEF5 could matter depends on whether native PRAMEF5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PRAMEF5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PRAMEF5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...